Isolation of Candidate Influenza Vaccine Viruses in Cell Culture
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
This Guideline lays down the quality recommendations for cells used to isolate candidate influenza vaccine viruses, the conditions under which the viruses are isolated and the subsequent passage of the viruses until the manufacturer's Master Seed is prepared under GMP conditions. This guideline replaces its draft version published under document reference EMA/CHMP/BWP/68803/2010. It should be read in conjunction with other relevant guideline documents like the introduction and general principles (4) and Part 1 of the Annex I to Directive 2001/83 or referneces like Ph. Eur. General chapter 5.2.3.
Get more information in the "Guideline on quality aspects on the isolation of candidate influenza vaccine viruses in cell culture".
Related GMP News
22.04.2026What are the GMP Requirements for ATMPs?
25.03.2026What are the GMP Requirements for Biotechnological Products?
18.03.2026Latest FDA Updates: Biosimilar Development Guidance
18.03.2026ECA ATMP Group publishes position paper on specifications considering patient-centricity
11.12.2025Utility of Comparative Efficacy Studies in Biosimilar Development
03.09.2025Standardisation of Monoclonal Antibodies (mAbs) by the EPC